At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

A peripheral nerve stimulator powered by AI and worn as a wristband improved essential tremor symptoms and patients’ ability to perform daily activities compared with a sham device, data from the ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Like a golf course, this week has a front half and a back half. But there’s a bit more rough and potential hazards on the back ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has turned to M&A to offset its recent ... therapy dapirolizumab pegol as well as Sage Therapeutics-partnered antidepressant zuranolone, although a lack of commentary on the latter in ...